The Next Ozempic Isn't Approved Yet. People Are Already Injecting It.

11% of Americans are already on a GLP-1 drug, per new Gallup data — and nearly 1 in 5 are using unapproved compounded versions the FDA calls "risky." What's coming next is, by the clinical numbers, more powerful than either approved drug — and it isn't on the market yet. Retatrutide, a once-weekly injectable developed by Eli Lilly, is still completing Phase 3 trials. No pharmacy can sell it. No doctor can prescribe it. And yet, for more than a year, people have been sourcing it anyway.

Why It's Being Called the "Next" GLP-1

Ozempic and Wegovy work on one hormone pathway (GLP-1). Mounjaro and Zepbound work on two (GLP-1 and GIP). Retatrutide is a triple agonist — GLP-1, GIP, and glucagon together — and in Lilly's own Phase 3 data, that combination has produced the largest weight-loss numbers seen yet in this drug class: roughly 28% average body weight lost at the highest dose.

Why People Aren't Waiting

Retatrutide's trial results have circulated widely on Reddit, TikTok, and fitness forums for over a year. Because the raw compound can legally be manufactured and sold for "laboratory research" purposes, a gray market of vendors sells it as a powder labeled "not for human consumption" — a legal loophole for the seller, and a real risk for the buyer.

What's Actually Been Found Inside the Vials

This is documented, not speculation:

• 50+ FDA warning letters issued to vendors illegally marketing retatrutide and related peptides since late 2024.
• Contents don't always match the label — independent testing has found vials sold as "retatrutide" containing salt water or insulin, a substitution that can cause dangerous blood sugar drops.
• Enforcement hasn't stopped sales — a Public Citizen investigation found most warned vendors kept advertising the drug months later.
• Even pharmaceutical-grade doses carry real side effects — trial data shows nausea, diarrhea, vomiting, and a nerve-related sensation called dysesthesia at meaningful rates.

None of this means the molecule itself lacks promise — the clinical data is genuinely strong. It means the version reaching people outside a trial has no verified purity, dose, or sterility, regardless of what the listing claims.

A documented case worth knowing: podcaster Bunnie Xo has publicly described a severe depressive episode, including suicidal thoughts, after using retatrutide — a reaction she attributes to the drug and has said isn't universal. It's a reminder that even reported "mild" side-effect profiles can look different for an individual.

What Legitimate Access Looks Like Right Now

There are exactly two legal paths to retatrutide today: enrolling in one of Lilly's ongoing Phase 3 trials (searchable on ClinicalTrials.gov), or waiting for FDA approval. Everything sold outside those two paths — including "research chemical" listings, some med-spa offerings, and telehealth storefronts — falls outside current law, regardless of how confident the marketing sounds.

The science behind retatrutide is real and well-documented in peer-reviewed trials. The version currently reaching consumers through gray-market channels is not the same product, has no verified quality control, and carries risks that go beyond typical GLP-1 side effects — including, in some tested cases, containing the wrong substance entirely. For anyone considering it: a clinical trial or an FDA-approved alternative, discussed with your doctor, is the only route with any safety data behind it today.